NCT07165444View on ClinicalTrials.gov

Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection

NARecruitingINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

September 11, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Potassium-Competitive Acid BlockerProton Pump InhibitorBismuth Based Quadruple TherapyTreatmentHelicobacter Pylori Infection
Interventions
DRUG

Potassium-Competitive Acid Blocker

Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.

DRUG

Proton Pump Inhibitor

Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.

Trial Locations (1)

31527

RECRUITING

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT07165444 - Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection | Biotech Hunter | Biotech Hunter